Cryo-Cell International Files 8-K

TL;DR

CRYO-CELL INTERNATIONAL, INC. filed an 8-K. Check for updates.

AI Summary

On March 25, 2024, CRYO-CELL INTERNATIONAL, INC. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates that Cryo-Cell International, Inc. is providing updates or disclosures to the SEC, which could contain important information for investors regarding the company's operations or financial status.

Risk Assessment

Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain information that inherently increases risk.

Key Players & Entities

• CRYO-CELL INTERNATIONAL, INC. (company) — Registrant
• 0000862692 (company) — Central Index Key
• 22-3023093 (company) — IRS Employer Identification No.
• 001-40767 (company) — Commission File Number
• March 25, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value CCEL NYSE American LLC

Filing Documents

• ccel-20240325.htm (8-K) — 43KB
• ccel-ex99_1.htm (EX-99.1) — 18KB
• 0000950170-24-036165.txt ( ) — 174KB
• ccel-20240325.xsd (EX-101.SCH) — 23KB
• ccel-20240325_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On March 25, 2024, Cryo-Cell International, Inc. ("Company" or "Cryo-Cell") issued a press release announcing plans to spin off its newly formed subsidiary, Celle Corp., to the Cryo-Cell shareholders and to explore all strategic alternatives for Cryo-Cell (post spin-off) to maximize shareholder value, including, but not limited to, equity and/or debt financings and/or the possible sale or merger of the company . A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

Financial Statements of Businesses Acquired

Financial Statements of Businesses Acquired. Not Applicable. Pro Forma Financial Information Not Applicable. Shell Company Transactions Not Applicable. Exhibits. Exhibit No. Description 99.1 Press Release dated March 25, 2024 104 Cover Page Interactive Data File (the cover page iXBRL tags are embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Cryo-Cell International, Inc. Date: March 26, 2024 By: /s/ David Portnoy David Portnoy, Chairman and Co-CEO

View Full Filing

View this 8-K filing on SEC EDGAR